Maintenance. We are currently updating the site. Please check back shortly
Members login
  • TrustLaw
  • Members Portal

Lilly depression drug fails late-stage trial

Source: Reuters - Thu, 5 Dec 2013 01:17 PM
Author: Reuters
Tweet Recommend Google + LinkedIn Bookmark Email Print
Leave us a comment

Dec 5 (Reuters) - Eli Lilly and Co on Thursday said its experimental drug to treat major depression failed to meet it primary goal in three late-stage trials and the drugmaker will not seek approval of the medicine for that condition.

The drug edivoxetine, a member of a family of medicines called norepinephrine reuptake inhibitors, was tested in combination with a member of a widely used class of depression treatments called selective serotonin reuptake inhibitors (SSRIs) in each of the three trials.

But after eight weeks of treatment, the combination of drugs that included edivoxetine did not prove superior to the SSRIs alone, thereby failing the main goal of the study.

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus
Topical content

Latest slideshow

See allSee all
Featured jobs